Clinical Trials · NCT00066690
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Enrollment
- 3,066
- Start date
- Dec 2003
- Locations
- 500 sites, 3 countries
- Primary endpoint
- Disease-free Survival